Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Salivary Gland Cancer | Research article

Lymph node ratio as a predictor for minor salivary gland cancer in head and neck

Authors: Hidenori Suzuki, Eiichi Sasaki, Gaku Takano, Seiya Goto, Daisuke Nishikawa, Shintaro Beppu, Hoshino Terada, Michi Sawabe, Nobuhiro Hanai

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

We investigate whether pathological continuous variables of lymph nodes were related with survival results of carcinomas of minor salivary gland carcinoma in head and neck.

Methods

Forty-four cases with minor salivary gland carcinoma who underwent both primary resection and neck dissection were retrospectively enrolled. The pathological continuous variables were evaluated by the number of positive lymph nodes, lymph node ratio, and log odds of positive lymph nodes. Receiver operating curve analysis was used for the cut-off values of the carcinoma-specific death. Log-rank test and Cox’s proportional hazards model were used for uni−/multi-variate survival analyses adjusting for pathological stage, respectively.

Results

Lymph node ratio = 0.05 as well as log odds of positive lymph nodes = − 2.73 predicted the carcinoma-specific death. Both lymph node ratio and log odds of positive lymph nodes were significantly related with survival outcomes by the univariate analysis. Lymph node ratio ≥ 0.05 was associated with shorter disease-specific (hazard ratio = 7.90, 95% confidence interval = 1.54–57.1), disease-free (hazard ratio = 4.15, 95% confidence interval = 1.48–11.2) and overall (hazard ratio = 4.84, 95% confidence interval = 1.05–24.8) survival in the multivariate analysis.

Conclusion

A higher lymph node ratio of minor salivary gland carcinoma is a predictor of shorter survival results.
Literature
8.
go back to reference Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 2016; 8th edition. New York: Springer; 2017.CrossRef Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 2016; 8th edition. New York: Springer; 2017.CrossRef
14.
go back to reference Zhang X, Yu F, Zhao Z, Mai J, Zhou Y, Liu X. The prognostic significance of lymph node ratio and log odds ratio in laryngeal squamous cell carcinoma. OTO Open. 2018;2(3):2473974X18792008.CrossRef Zhang X, Yu F, Zhao Z, Mai J, Zhou Y, Liu X. The prognostic significance of lymph node ratio and log odds ratio in laryngeal squamous cell carcinoma. OTO Open. 2018;2(3):2473974X18792008.CrossRef
15.
go back to reference Yildiz MM, Petersen I, Eigendorff E, Schlattmann P, Guntinas-Lichius O. Which is the most suitable lymph node predictor for overall survival after primary surgery of head and neck cancer: pN, the number or the ratio of positive lymph nodes, or log odds? J Cancer Res Clin Oncol. 2016;142(4):885–93. https://doi.org/10.1007/s00432-015-2104-1.CrossRefPubMed Yildiz MM, Petersen I, Eigendorff E, Schlattmann P, Guntinas-Lichius O. Which is the most suitable lymph node predictor for overall survival after primary surgery of head and neck cancer: pN, the number or the ratio of positive lymph nodes, or log odds? J Cancer Res Clin Oncol. 2016;142(4):885–93. https://​doi.​org/​10.​1007/​s00432-015-2104-1.CrossRefPubMed
Metadata
Title
Lymph node ratio as a predictor for minor salivary gland cancer in head and neck
Authors
Hidenori Suzuki
Eiichi Sasaki
Gaku Takano
Seiya Goto
Daisuke Nishikawa
Shintaro Beppu
Hoshino Terada
Michi Sawabe
Nobuhiro Hanai
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08877-3

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine